Drug Discovery Featured Articles & Applications
-
What The China Biotech Debate Reveals About U.S. Drug Discovery
8/17/2026
Peter Kolchinsky and Jason Kelly sparred over China’s biotech rise and what it means for U.S. drug discovery, investment, and strategic control.
-
Closing The Loop Between AI And Experimental Biology
8/17/2026
We caught up with Rosie Rodriguez, Ph.D., president of growth at Relation, to discuss AI’s place in accelerating discovery
-
Beyond Apoptosis: Context Is The Target
8/17/2026
Cells that evade apoptosis do not necessarily evade death; they may remain vulnerable to ferroptosis, pyroptosis, necroptosis, or another regulated cell death program.
-
Alpha-Synuclein Is Not One Target
8/14/2026
Alpha-synuclein is not one target, and a nanobody is not a smaller antibody with automatic access.
-
Early Decisions That Shape Success In CNS Drug Development And Commercialization, Part 2
8/11/2026
In part 2, Ginger continues to provide insights for R&D teams on CNS development and commercialization.
-
July Update — U.S. Generic Drug Tariffs: Implications For Pharma And Outsourcing
8/7/2026
Mathini Ilancheran updates us on how delayed U.S. tariffs on generic drug imports could reshape supply, sourcing, and trial planning.
-
Why Ending Rh Disease Requires More Than A Breakthrough (Part 3 of 3)
8/5/2026
Rh disease has been preventable for decades. Yet babies still die worldwide because access, supply, and infrastructure have not caught up.
-
Early Decisions That Shape Success In CNS Drug Development And Commercialization, Part 1
8/4/2026
In part 1, we caught up with Ginger Johnson, SVP and neuroscience lead at Lumanity, to discuss how companies can connect the science to the realities of CNS drug development earlier
-
The Changing Role Of Computational Mechanics In Drug Discovery
8/3/2026
Computational models will never replace experimental biology, but their emerging role is different.
-
Beyond Binder Design: Why AI's Next Frontier Is Designing Multispecific Antibodies
7/31/2026
Many of the therapies with the greatest potential to improve patient outcomes are complex multispecifics, where the data simply doesn't exist.